These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16585921)

  • 41. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk.
    Rebbeck TR; Troxel AB; Shatalova EG; Blanchard R; Norman S; Bunin G; Demichele A; Schinnar R; Berlin JA; Strom BL
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1318-20. PubMed ID: 17548708
    [No Abstract]   [Full Text] [Related]  

  • 43. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution.
    Chlebowski RT; Prentice RL
    J Natl Cancer Inst; 2008 Oct; 100(19):1341-3. PubMed ID: 18812547
    [No Abstract]   [Full Text] [Related]  

  • 44. Estrogen-progestogen replacement therapy and ovarian cancer: an update.
    La Vecchia C
    Eur J Cancer Prev; 2006 Dec; 15(6):490-2. PubMed ID: 17106327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hormone replacement therapy said to be rarely justified for breast cancer patients.
    Oncology (Williston Park); 1994 Jun; 8(6):58. PubMed ID: 8074985
    [No Abstract]   [Full Text] [Related]  

  • 46. Re: "Increased risk of breast cancer with alcohol consumption in postmenopausal women".
    Friedenreich CM
    Am J Epidemiol; 1994 Mar; 139(5):541-2. PubMed ID: 8154479
    [No Abstract]   [Full Text] [Related]  

  • 47. Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    Eisinger F; Huiart L
    J Natl Cancer Inst; 2009 Feb; 101(4):277; author reply 277-8. PubMed ID: 19211447
    [No Abstract]   [Full Text] [Related]  

  • 48. Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?
    Paul C
    Int J Epidemiol; 2008 Jun; 37(3):638-40. PubMed ID: 18375444
    [No Abstract]   [Full Text] [Related]  

  • 49. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
    Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Moderate alcohol drinking is a risk factor for breast cancer].
    Fumagalli NT; Saitz R
    Rev Med Suisse; 2012 Mar; 8(333):658. PubMed ID: 22506451
    [No Abstract]   [Full Text] [Related]  

  • 52. The estrogen paradox.
    Santen RJ; Allred DC
    Nat Clin Pract Endocrinol Metab; 2007 Jul; 3(7):496-7. PubMed ID: 17519914
    [No Abstract]   [Full Text] [Related]  

  • 53. Have we found the ultimate risk factor for breast cancer?
    Vogel VG; Taioli E
    J Clin Oncol; 2006 Apr; 24(12):1791-4. PubMed ID: 16567765
    [No Abstract]   [Full Text] [Related]  

  • 54. Another opportunity for prevention: assessing alcohol use by women attending breast screening services in Lismore, NSW.
    Daly MD; Passey ME; Harvey AJ
    N S W Public Health Bull; 2009; 20(5-6):90-2. PubMed ID: 19552856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Breast density: a major parameter to follow during hormone replacement therapy].
    Gairard B; Guldenfels C; Haehnel P; Mathelin C
    Gynecol Obstet Fertil; 2009; 37(7-8):657-60. PubMed ID: 19577502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future prospects for the prevention and cure of breast cancer.
    Fentiman IS
    Eur J Cancer; 2000 Jun; 36(9):1085-8. PubMed ID: 10854940
    [No Abstract]   [Full Text] [Related]  

  • 57. Hormone therapy and breast cancer risk.
    Foidart JM; Desreux J; Pintiaux A; Gompel A
    Climacteric; 2007 Oct; 10 Suppl 2():54-61. PubMed ID: 17882674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The risk of getting breast cancer after hormonal replacement therapy for menopause is stopped].
    Jamin C; Madelenat P
    Gynecol Obstet Fertil; 2008 Nov; 36(11):1067-9. PubMed ID: 18951058
    [No Abstract]   [Full Text] [Related]  

  • 59. [Is estrogen replacement therapy contraindicated in breast cancer?].
    Iversen OE
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):611-2. PubMed ID: 16505873
    [No Abstract]   [Full Text] [Related]  

  • 60. Estrogen, alcohol consumption, and breast cancer.
    Fernandez SV
    Alcohol Clin Exp Res; 2011 Mar; 35(3):389-91. PubMed ID: 22132831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.